Mutational spectrum
TPM3: mainly dominant, missense variants; 1,2 however, some recessive variants have been described. 3, 4 A 1 bp recessive deletion occurs as a founder variant in the Turkish population. 5 NEB: all of the over 140 variants identified to date are recessive and the patients are usually compound heterozygous. The majority of the variants are either frameshift or nonsense variants, but also missense variants, and point variants and deletions affecting splice sites are known. 6, 7 An in-frame deletion of exon 55 is present in the Ashkenazi Jewish population at a carrier frequency of~1 in 108. 8 Some patients present with a distal myopathy, with their skeletal muscle biopsies containing nemaline bodies, both nemaline bodies and cores, or no nemaline bodies. 9, 10 Rare cases of core-rod myopathy with generalised muscle weakness may also be caused by NEB variants. 11 ACTA1: over 200 different variants identified, with the majority causing nemaline myopathy, or nemaline myopathy with other features (eg cores, actin aggregates, intranuclear rods and zebra bodies). 12 Of these, most variants are dominant, missense, and have arisen de novo. 13 About 10% are recessive variants. Most recessive variants are genetic or functional null variants 13 but recently recessive ACTA1 disease with retention of skeletal muscle actin expression was described in a family presenting with a rigid spine syndrome. 14 Dominant inheritance is less common, and only seen in families with a milder phenotype. 13 Somatic mosaicism is possible with dominant variants. 15 Some variants can cause hypercontractile skeletal muscle rather than weakness. 16 TPM2: Two heterozygous, dominant missense variants causing nemaline myopathy are known. 17 Also a homozygous null variant in a patient with nemaline and Escobar syndrome, 18 and a dominant heterozygous variant in a mother with nemaline myopathy and her daughter with cap myopathy 19 have been identified. A K7del variant was identified in a family with nemaline bodies and minicores (presenting as a distal myopathy), and also in four unrelated families with distal arthrogryposis type 7 with nemaline bodies. 20 The K7del variant also causes progressive skeletal muscle contractures, most probably because of the hypercontractility caused by the mutant protein in nemaline myopathy and/or core-rod myopathy patients. 21 TNNT1: a recessive nonsense founder variant is present in the Old Order Amish population. This produces a characteristic progressive nemaline myopathy with tremors and contractures. 22 TNNT1 variants have now been identified outside the Amish population. 23 KBTBD13: three dominant missense variants have been identified. 24 There was phenotypic variability, with some variant carriers exhibiting only very mild proximal leg weakness on targeted examination.
CFL2: homozygous missense variants have been identified in two families, 25, 26 and a homozygous 4 bp deletion identified in another family. 27 The severity of the disease is greater in the family with the homozygous null variant.
KLHL40: homozygous or compound heterozygous variants (mainly missense, but also frameshift, splice site and nonsense variants) cause severe autosomal recessive nemaline myopathy with prenatal onset of symptoms, including foetal akinesia or hypokinesia and contractures. 28 At birth, the children may have fractures, respiratory failure and severe swallowing difficulties. 28 KLHL41: Recessive homozygous or compound heterozygous variants have been reported, with frameshift variants leading to a severe phenotype with neonatal death, and missense variants compatible with survival into late childhood or early adulthood. 29 LMOD3: Recessive homozygous and compound heterozygous variants cause severe, usually lethal nemaline myopathy. 30 Regularly updated variant databases exist for ACTA1, CFL2, KBTBD13, KLHL40, NEB, TNNT1, TPM2 and TPM3 at the Leiden Muscular Dystrophy pages (http://www.dmd.nl).
Analytical methods
The main analytical method has been bi-directional Sanger sequencing of the entire coding region of the individual genes. If the family structure is amenable, linkage analysis for NEB may be useful to prescreen, because of the large size of the gene. Next-generation sequencing now allows for simultaneous analysis of all genes in a patient through whole-exome sequencing. Alternatively sub-exomic sequencing using a panel of selected genes can include all known nemaline myopathy genes. 31 It should be noted however that limitations of current high throughput sequencing technologies prevent complete screening of all exons in all genes (eg, regions of genes that have high GC content or are repetitive).
Analytical validation
Variants should be confirmed by resequencing using a fresh dilution of genomic DNA. Putative variants identified through next-generation sequencing methods should be confirmed by Sanger sequencing. Special care should be taken in interpreting missense variants in the nebulin gene as affecting function. 10 1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) For the most part, the frequency of the disease is unknown. In Finland, the birth incidence has been estimated to be 0.02 per 1000 live births. 32 De novo dominant variants in ACTA1 and recessive variants in NEB are the most common causes of NEM. 33, 34 1.9 If applicable, prevalence in the ethnic group of investigated person Recessive founder variants are known to exist in particular genes in specific populations: TNNT1 in the Amish; 22 NEB in the Ashkenazi Jewish 8 and in the Finnish population. 10 ACTA1 in the Pakistani community in England, and in French and Spanish Roma; 13 TPM3 in the Turkish population; 5 and KLHL40 in Japanese persons. 28 These specific cases aside, no clear differences in prevalence rates are known between different ethnic groups.
Diagnostic setting
Comment: requests for predictive testing are not common because of the early onset of the disease, but may be offered in families with childhood or late-onset forms of the disease. 
TEST CHARACTERISTICS

Clinical Sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity is dependent on factors such as age, inheritance pattern and additional clinical features. Because of the genetic heterogeneity, and particularly the difficulty of screening NEB, full screening of all known nemaline myopathy genes has historically not been possible. However, next-generation technologies are now getting closer to such screening. If full screening were to be undertaken, it may be estimated that~75% of patients would have a variant(s) identified. 6,13
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Probably 100%. or TPM3 can cause congenital myopathies with neuromuscular transmission defects that can benefit from treatment with anticholinesterase therapy. 52, 53 Nemaline bodies can also be identified as secondary features, such as in mitochondrial disorders 54 and HIV. 55 3.1.2 Describe the burden of alternative diagnostic methods to the patient Nemaline myopathy is both a clinical and, significantly, a histopathological/electron microscopic diagnosis. Therefore, a thorough assessment including a detailed evaluation of clinical and pathological features should be performed along with genetic testing. As such, histopathology and electron microscopy are not diagnostic alternatives, rather prerequisites to genetic testing. Nevertheless, muscle biopsy is an invasive procedure, and appropriate histological and electron microscopic examination requires proximity to a specialised laboratory set up.
3.1.3
How is the cost effectiveness of alternative diagnostic methods to be judged? Not applicable.
Will disease management be influenced by the result of a genetic test?
No □ Yes ⊠ Therapy (please describe)
Presently, the treatment of patients is based on symptom management, which would occur regardless of the genetic diagnosis. However, an accurate genetic diagnosis will undoubtedly be extremely important for any causal therapies once they are developed.
Prognosis (please describe)
Varied, as nemaline myopathy can be severe (foetal or congenital presentation) through to mild, 56 
Predictive Setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Predictive testing is usually only applicable for the milder versions of nemaline myopathy, as most often the disease presents before, at or shortly after birth.
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe)
The positive test result may influence lifestyle choices for later onset of disease, for example deciding which career to pursue (eg, an office job compared with something physical), whether to travel at a young age when mobility is not affected compared with later in life and whether to have a house on one level as opposed to over multiple stories (eg, the latter would involve climbing lots of stairs which might become problematic). Respiratory precautions and self-monitoring for sleeprelated breathing problems may be advised. A positive test will greatly influence prevention, through the availability of prenatal or preimplantation diagnosis for the family. Yes, but owing to very early disease onset in most cases, it is infrequently encountered.
Prenatal diagnosis
(To be answered if in 1.10 'D' was marked) 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? Yes. In cases where dominant de novo variants have been identified in an affected child, genetic counselling may be difficult, as the recurrence risk is between 0 and 25% because of the possibility of gonadal mosaicism. However, prenatal genetic testing of an at-risk pregnancy is accurate.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).
Yes, particularly if a variant/s are identified. An accurate genetic diagnosis often ends a lengthy diagnostic odyssey for the patient and their family, removing the psychological effects of an absent disease, and can sometimes influence possible prognosis. An accurate genetic diagnosis can crucially indicate the mode of inheritance and underpins genetic counselling, including options such as prenatal and preimplantation testing.
